Last updated: February 24, 2026
Case Overview
Endo Pharmaceuticals Inc. filed a patent infringement lawsuit against Amneal Pharmaceuticals LLC in the U.S. District Court for the Southern District of New York (Case No. 1:12-cv-08115). The case involves allegations that Amneal infringed upon Endo’s patents related to controlled-release formulations of certain opioid pharmaceutical products.
Timeline and Core Allegations
- Filing Date: October 2, 2012
- Legal Allegation: Endo claimed Amneal produced, marketed, or sold generic versions of Endo’s branded opioids without licensing rights, infringing on patents covering formulation and methods.
- Patent Focus: The dispute primarily centered on U.S. Patent No. 7,773,572, covering a specific controlled-release opioid formulation.
Patent Details
| Patent Number |
Issue Date |
Key Claims |
| 7,773,572 |
August 10, 2010 |
Claims cover a controlled-release opioid with specific coating and dissolution properties designed to extend release over 12 hours. |
The patent claims a formulation with a unique combination of excipients and coating technology to ensure extended release without dose dumping.
Court Proceedings and Developments
Initial Complaint
Endo’s complaint alleged that Amneal's generic product infringed the patent through its "A" and "B" label versions. Endo sought to prevent Amneal from entering the market with its generic and for monetary damages.
Patent Validity and Infringement Challenges
Amneal filed a motion for summary judgment asserting invalidity of the patent due to anticipation and obviousness. The core arguments were:
- The claimed formulation was obvious in light of prior art references (e.g., earlier extended-release formulations).
- The patent lacked novelty due to prior patents that disclosed similar excipient combinations.
Court's Ruling
In 2015, the court denied Amneal’s motions, finding that genuine issues of material fact remained about whether the patent was invalid and whether infringement existed.
Settlement and Resolution
The litigation settled in 2016. Endo and Amneal agreed to a royalty-bearing license, with Amneal permitted to market its generic product under certain conditions. The case did not result in a final ruling on patent validity or infringement.
Legal Significance
- The case illustrates the typical lifecycle of patent disputes involving timing of generic market entry.
- The settlement underscores the importance of patent protections in controlling drug market access.
- It highlights challenges faced by generic manufacturers regarding patent validity, especially in complex formulations.
Key Patent Litigation Elements
| Aspect |
Details |
| Patent Type |
Method of formulation (composition patent) |
| Main Legal Issue |
Patent infringement and patent validity |
| Defense Strategies |
Obviousness, anticipation based on prior art |
| Court Outcome |
Denial of summary judgment motions; settlement before trial |
Impact on Industry
This case exemplifies the strategic battles around patent enforcement between brand-name and generic drug manufacturers. It demonstrates how patent arguments—particularly on obviousness—are central in pharmaceutical patent litigation.
Key Takeaways
- Patent validity defenses in pharmaceutical litigation often hinge on prior art and obviousness.
- Settlement agreements can resolve disputes without final judicial rulings.
- Patent overlap with existing formulations complicates generic approval processes.
- The case highlights the need for robust claim drafting and early patent clearance strategies.
- Litigation outcomes influence market entry timing and royalty arrangements.
FAQs
1. What legal grounds did Amneal use to challenge Endo’s patent?
Amneal claimed the patent was obvious based on prior art disclosures.
2. How typical is settlement in pharmaceutical patent disputes?
Settlement is common, often to avoid costly, lengthy trials and to secure licensing terms.
3. Did the case influence subsequent generic entry?
Yes, the settlement permitted Amneal to market its generic after licensing, affecting market competition.
4. What are the key patent features protected in this case?
The patent protects specific controlled-release formulations with unique coating and excipient combinations.
5. How does this case reflect patent challenges in the opioid market?
It shows the emphasis on formulation patents to extend exclusivity amidst increasing patent challenges.
References
[1] U.S. District Court for the Southern District of New York. (2012). Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals, LLC. Case No. 1:12-cv-08115.
[2] USPTO. (2010). U.S. Patent No. 7,773,572.
